Advertisement

All Three Vasopressin Receptor Sub-Types are Expressed by Small-Cell Carcinoma

  • William G. North
  • Michael J. Fay
  • Jinlin Du
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 449)

Abstract

We have demonstrated that vasopressin gene-related products are universal lineage markers of small-cell carcinoma of the lung (SCCL) and vasopressin is therefore most likely produced by all small-cell tumors1,2. This peptide has been found by others to promote tumor growth3,4. Such a mitogenic role, that involves Ca2+ mobilization and increases in MAP kinase activity, has been presumed by several investigators to be exercised through a single vasopressin receptor sub-type, namely the V1a receptor. In addition, a possible explanation advanced for the Ca2+ refractiveness to vasopressin of variant (dedifferentiated and drug-resistant) SCCL was a lost capacity to express this receptor5. However, we recently demonstrated that functional V­1, receptors are present in both classical and variant SCCL6. We have now employed the techniques of RT-PCR, cloning, DNA sequencing, Northern analysis, and Western analysis, to examine the capacity of both classical and variant forms of SCCL to produce all three vasopressin receptor sub-types, namely V 1a receptors, V1b receptors, and V2 receptors.

Keywords

Receptor mRNA Nephrogenic Diabetes Insipidus Vasopressin Receptor Normal Human Lung Tumor Growth Inhibitory Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    North WG 1991 Neuropeptide production by small cell carcinoma: vasopressin and oxytocin as plasma markers of disease. J Clin Endocrinol Metab 73:1316–1320PubMedCrossRefGoogle Scholar
  2. 2.
    Friedmann AS, Malott KA, Memoli VA, Pai SI, Yu X, North WG 1994 Products of vasopressin gene expression in small-cell carcinoma of the lung. Br J Cancer 69:260–263PubMedCrossRefGoogle Scholar
  3. 3.
    Woll PJ, Rozengurt E 1989 Neuropeptides as growth regulators. Br Med Bull 45:292–505Google Scholar
  4. 4.
    Zachary I, Sinnett-Smith J, Rozengurt E 1991 Stimulation of tyrosine kinase activity after addition of bonibesin, vasopressin, and endothelin to intact cells. J Biol Chem 266:24126–24133PubMedGoogle Scholar
  5. 5.
    Bunn PA, Dienhart DG, Chan D, Tagawa M, Jewett P 1992 Effects of neuropeptides on human lung and breast cancer cells. Monogr Natl Cancer Inst 13:145–151PubMedGoogle Scholar
  6. 6.
    North WG, Fay MJ, Longo K, Du J 1997 Functional Vl vasopressin receptors are present in both variant and classical forms of small-cell tumor cells. Peptides 18:985–993PubMedCrossRefGoogle Scholar
  7. 7.
    Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E 1994 Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem 269:3304–3310PubMedGoogle Scholar
  8. 8.
    Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S, Kawashima H 1994 Molecular cloning and functional expression of a cDNA encoding the human Vlb vasopressin receptor. J Biol Chem 269:27088–27092PubMedGoogle Scholar
  9. 9.
    Birnbaumer M, Siebold A, Rosenthal W, Bichet DG 1993 The human ADH receptor: the gene, the cDNA, the protein. In: Gross P, Richter D, Robertson GI (eds) Vasopressin. John Libbey Eurotext, Paris, pp 19–31Google Scholar
  10. 10.
    Hirasawa A, Shibata K, Kotosai K, Tsujimoto G 1994 Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 203:72–79PubMedCrossRefGoogle Scholar
  11. 11.
    Fay MJ, Du J, Yu X, North WG 1996 Evidence for expression of vasopressin V2 receptor mRNA in human lung. Peptides 17:477–481PubMedCrossRefGoogle Scholar
  12. 12.
    de Keyzer Y, Auzan C, Lenne F, Beldjord C, Thibonnier M, Bertagna X, Clauser E 1994 Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett 356:215–220PubMedCrossRefGoogle Scholar
  13. 13.
    Fahrenholz F, Akhunddova A, Buchner H, Gorbulev V 1993 V2 Lysine vasopressin receptor and oxytocin receptor from pig LLC-PK1 cells: two new members of the vasopressin-oxytocin receptor family. In: Gross P, Richter D, Robertson GI (eds) Vasopressin. John Libbey Eurotext, Paris, pp 45–57Google Scholar
  14. 14.
    Brownstein MJ, Lolait SJ 1993 Hereditary nephrogenic diabetes insipidus. In: Gross P, Richter D, Robertson GI (eds) Vasopressin. John Libbey Eurotext, Paris, pp 33–43Google Scholar
  15. 15.
    Wimalawansa SJ 1995 Purification and biochemical characterization of neuropeptide Y2 receptor. Amer Soc Biochem Molec Biol 270:18523–18530Google Scholar
  16. 16.
    Longo KA, Fay MJ, North WG 1996 Evidence for the expression of a novel vasopressin-activated calcium mobilizing receptor (VACM-1) in human breast cancer and lung cancer. Mol Biol Cell 7:3761Google Scholar
  17. 17.
    Burnatowska-Hledin MA, Spielman WS, Smith WL, Shi P, Meyer JM, Dewitt DL 1995 Expression cloning of an AVP-activated, calcium-mobilizing receptor from rabbit kidney medulla. Am J Physiol 268:F1198–210PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • William G. North
    • 1
  • Michael J. Fay
    • 1
  • Jinlin Du
    • 1
  1. 1.Department of PhysiologyDartmouth Medical SchoolLebanonUSA

Personalised recommendations